Getting a GLP-1 Prescription With a BMI Under 30: The Comorbidity Pathways

The 27-to-30 BMI Zone: You're Eligible, But You Need Documentation

If your BMI falls between 27 and 29.9, you're in what prescribers call the "comorbidity pathway." The FDA approvals for both semaglutide (Wegovy) and tirzepatide (Zepbound) explicitly include patients at BMI ≥ 27 with at least one weight-related condition. You don't need to be severely obese to benefit from these medications — but you do need documentation.

The documentation requirement is where most sub-30 applicants run into trouble. It's not enough to tell your prescriber you have high blood pressure. Your medical record needs to show a diagnosis code, a recorded measurement, or a current prescription for the condition. Telehealth platforms that rely on self-reported questionnaires may accept your statement at face value, but insurance-based prescriptions require clinical evidence.

Here's the practical reality: if you've ever been diagnosed with hypertension, prescribed a statin, used a CPAP machine, or had an A1C reading of 5.7 or higher, you likely qualify. The challenge is making sure that documentation reaches whoever is writing your prescription.

Pathway by Pathway: Which Comorbidity Opens Which Door

Type 2 Diabetes / Prediabetes

This is the strongest comorbidity for GLP-1 access because semaglutide and tirzepatide were originally approved for diabetes management. If you have an A1C of 5.7–6.4 (prediabetes) or ≥ 6.5 (diabetes), your prescriber has both an obesity indication and a metabolic indication to draw from. Insurance approval rates are highest in this category.

Hypertension

A blood pressure reading ≥ 130/80 mmHg or a current antihypertensive prescription qualifies. This is the most common comorbidity cited on GLP-1 applications because so many adults with a BMI of 27-30 also have elevated blood pressure — often undiagnosed until they get a screening.

Obstructive Sleep Apnea

Particularly strong since the FDA approved Zepbound for moderate-to-severe OSA in late 2024. If you have a documented sleep study showing an AHI ≥ 15 (or ≥ 5 with symptoms), this is an increasingly well-supported pathway.

Cardiovascular Disease

The SELECT trial data showing cardiovascular risk reduction with semaglutide strengthened this pathway significantly. A history of heart attack, stroke, peripheral artery disease, or documented atherosclerosis gives prescribers strong clinical justification.

How Telehealth Platforms Handle the Under-30 BMI Question

Every legitimate telehealth platform will ask for your height, weight, and health history during intake. How they verify this information — and what they do with borderline cases — varies widely.

Some platforms require you to upload a full-body photo alongside your intake form. Others ask for recent lab work or medical records. A few conduct video consultations where the prescriber can ask follow-up questions. The Yale secret shopper study found that some platforms approved prescriptions even when required photos were never submitted, which suggests inconsistent enforcement of their own eligibility criteria.

For the cash-pay compounded pathway, the clinical bar tends to be lower in practice — a BMI of 27 with self-reported hypertension will generally get you approved. But lower clinical scrutiny is a double-edged sword: faster access also means less personalized medical guidance.

If your BMI is close to the line, consider getting a clinical measurement from your PCP first. A documented BMI of 27.5 from an in-person visit, recorded in your medical chart, is stronger documentation than a self-reported number on a telehealth form.

The Self-Reported BMI Problem

Here's a reality that the industry doesn't talk about openly: BMI on telehealth intake forms is almost always self-reported. You enter your height and weight, the system calculates your BMI, and that number becomes part of your medical file. No one is stepping on a scale or measuring your height.

This creates both an ethical and practical issue. Some patients underestimate their weight (qualifying becomes easier if your actual BMI is higher than you think), while others overestimate their height (which lowers the calculated BMI). The Yale study noted this as a systemic vulnerability in online GLP-1 prescribing.

The honest approach is the safest one: report your actual numbers, bring supporting documentation for any comorbidities, and let the prescriber make an informed clinical decision. If you don't actually qualify, starting a GLP-1 without appropriate medical oversight creates risks that aren't worth the potential benefit.